Your browser doesn't support javascript.
loading
The fatigue after infusion or transfusion pilot trial and feasibility study: A three-armed randomized pilot trial of intravenous iron and blood transfusion for the treatment of postpartum anemia.
Caljé, Esther; Oyston, Charlotte; Wang, Zeke; Bloomfield, Frank; Marriott, Joy; Dixon, Lesley; Groom, Katie.
  • Caljé E; Liggins Institute, The University of Auckland, Auckland, New Zealand.
  • Oyston C; Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Wang Z; Middlemore Hospital, Auckland, New Zealand.
  • Bloomfield F; Liggins Institute, The University of Auckland, Auckland, New Zealand.
  • Marriott J; Liggins Institute, The University of Auckland, Auckland, New Zealand.
  • Dixon L; Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Groom K; New Zealand College of Midwives, Christchurch, New Zealand.
Transfusion ; 64(2): 301-314, 2024 02.
Article en En | MEDLINE | ID: mdl-38149691
ABSTRACT

BACKGROUND:

Evidence for the management of moderate-to-severe postpartum anemia is limited. A randomized trial is needed; recruitment may be challenging. STUDY DESIGN AND

METHODS:

Randomized pilot trial with feasibility surveys. INCLUSION hemoglobin 65-79 g/L, ≤7 days of birth, hemodynamically stable. EXCLUSION ongoing heavy bleeding; already received, or contraindication to intravenous (IV)-iron or red blood cell transfusion (RBC-T). Intervention/control IV-iron; RBC-T; or IV-iron and RBC-T. PRIMARY

OUTCOME:

number of recruits; proportion of those approached; proportion considered potentially eligible. SECONDARY

OUTCOMES:

fatigue, depression, baby-feeding, and hemoglobin at 1, 6 and 12 weeks; ferritin at 6 and 12 weeks. Surveys explored attitudes to trial participation.

RESULTS:

Over 16 weeks and three sites, 26/34 (76%) women approached consented to trial participation, including eight (31%) Maori women. Of those potentially eligible, 26/167 (15.6%) consented to participate. Key participation enablers were altruism and study relevance. For clinicians and stakeholders the availability of research assistance was the key barrier/enabler. Between-group rates of fatigue and depression were similar. Although underpowered to address secondary outcomes, IV-iron and RBC-T compared with RBC-T were associated with higher hemoglobin concentrations at 6 (mean difference [MD] 11.7 g/L, 95% confidence interval [CI] 2.7-20.7) and 12 (MD 12.8 g/L, 95% CI 1.5-24.2) weeks, and higher ferritin concentrations at 6 weeks (MD 136.8 mcg/L, 95% CI 76.6-196.9).

DISCUSSION:

Willingness to participate supports feasibility for a future trial assessing the effectiveness of IV-iron and RBC-T for postpartum anemia. Dedicated research assistance will be critical to the success of an appropriately powered trial including women-centered outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Transfusión de Eritrocitos / Periodo Posparto / Hematínicos / Anemia Límite: Female / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Transfusión de Eritrocitos / Periodo Posparto / Hematínicos / Anemia Límite: Female / Humans Idioma: En Año: 2024 Tipo del documento: Article